Division of Infectious Diseases and Hospital Epidemiology,University Hospital Basel,Basel,Switzerland.
Department of Anesthesiology, Operative Intensive Care, Preclinical Emergency Medicine and Pain Management,University Hospital Basel,Basel,Switzerland.
Infect Control Hosp Epidemiol. 2019 Apr;40(4):408-413. doi: 10.1017/ice.2019.5. Epub 2019 Feb 21.
To determine whether colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-PE) predicts the risk for subsequent infection and impacts carbapenem-consumption and outcome in intensive care unit (ICU) patients.
Prospective cohort study.
The 2 ICUs in the University Hospital Basel in Switzerland.
All patients admitted to the 2 ICUs providing mechanical ventilation and an expected ICU stay >48 hours.
Patients were routinely screened for ESBL-PE carriage by rectal swab on admission. Competing risk regression analyses were applied to calculate hazard ratios (HRs) for infection with ESBL-PE and mortality. Length of hospital stay, length of ICU stay, and duration of carbapenem exposure were compared using the Mann-Whitney U test.
Among 302 patients, 24 (8.0%) were colonized with ESBL-PE on ICU admission. Infections with ESBL-PE occurred in 4 patients, of whom 3 (75%) were identified as ESBL-PE colonized on admission. ESBL-PE colonization on admission was associated with subsequent ESBL-PE infection (hazard ratio [HR], 25.52; 95% confidence interval [CI], 2.40-271.41; P = .007) and exposure to carbapenems (HR, 2.42; 95% CI, 1.01-5.79; P = .047), whereas duration of carbapenem exposure did not differ in relation to ESBL-PE colonization (median, 7 days [IQR, 3-8 days] vs median, 6 days [IQR 3-9 days]; P = 0.983). Patients colonized with ESBL-PE were not at increased risk for death overall (HR, 1.00; 95% CI, 0.44-2.30; P = .993) or death attributable to infection (HR, 1.20; 95% CI, 0.28-5.11; P = .808).
Screening strategies for detection of ESBL-PE colonization on ICU admission may allow the identification of patients at highest risk for ESBL-PE infection and the correct allocation of empiric carbapenem treatment.
确定产超广谱β-内酰胺酶肠杆菌科(ESBL-PE)定植是否预测随后感染的风险,并影响重症监护病房(ICU)患者的碳青霉烯类药物使用和结局。
前瞻性队列研究。
瑞士巴塞尔大学医院的 2 个 ICU。
所有入住提供机械通气和预计 ICU 住院时间>48 小时的 2 个 ICU 的患者。
患者在入院时通过直肠拭子常规筛查 ESBL-PE 定植。应用竞争风险回归分析计算 ESBL-PE 感染和死亡率的风险比(HR)。使用 Mann-Whitney U 检验比较住院时间、ICU 住院时间和碳青霉烯类药物暴露时间。
在 302 名患者中,有 24 名(8.0%)在入住 ICU 时定植 ESBL-PE。4 名患者发生 ESBL-PE 感染,其中 3 名(75%)入院时被确定为 ESBL-PE 定植。入住 ICU 时 ESBL-PE 定植与随后的 ESBL-PE 感染(HR,25.52;95%置信区间 [CI],2.40-271.41;P=.007)和碳青霉烯类药物暴露(HR,2.42;95%CI,1.01-5.79;P=.047)相关,而碳青霉烯类药物暴露时间与 ESBL-PE 定植无关(中位数,7 天 [IQR,3-8 天] vs 中位数,6 天 [IQR,3-9 天];P=0.983)。定植 ESBL-PE 的患者总体死亡率无增加(HR,1.00;95%CI,0.44-2.30;P=.993)或归因于感染的死亡率(HR,1.20;95%CI,0.28-5.11;P=.808)。
在 ICU 入院时进行 ESBL-PE 定植筛查策略可能有助于识别感染 ESBL-PE 风险最高的患者,并正确分配经验性碳青霉烯类药物治疗。